

## Title page

**Title:** Monkeypox in the New York metropolitan area, Summer 2022

**Authors:** Rachel Gnanaprakasam, Marina Keller, Rebecca Glassman, Marc Y El Khoury, Donald Chen, Nicholas Feola, Jared Feldman, Vishnu Chaturvedi

**Affiliations:** Westchester Medical Center, Valhalla, New York, USA

**Correspondence:** Marina Keller [marina.keller@wmchealth.org](mailto:marina.keller@wmchealth.org)

**Keywords:** Monkeypox, Orthopox, outbreak, tecovirimat, vaccine

**Abstract text:** Early in the 2022 Monkeypox global outbreak, caseloads in the New York metropolitan area climbed rapidly before other US urban areas. We summarize our monkeypox clinical experience detecting, treating, and vaccinating during a quickly evolving emerging infection.

### *Statements*

**Ethical statement:** Institutional Review Board exemption was granted for this study.

**Funding statement:** No funding was obtained

**Acknowledgements:** Dr Humayun Islam, Marie Yezzo, Sherita Bernard, Justin Williams, Keri Tone, Dan Amarillo, Diana Guevara, Claudia Dones, Kristy Greene

**Conflict of interest:** None

**Authors' contributions:** Each author actively participated in data collection, analysis and editing of the manuscript.

**Collaborators:** None

Monkeypox (MPX) is a zoonotic disease caused by a double-stranded DNA monkeypox virus (MPXV) from the *Poxviridae* family that includes smallpox and cowpox viruses [1,2]. Until recently, MPX circulated in a few Western and Central African countries, with cases elsewhere in the globe limited to small, short-lived outbreaks [3,4]. Starting in May of 2022, a global outbreak of monkeypox was reported, which grew to over 77,000 cases in 106 countries [5,6,7]. In the USA, the caseload started to climb rapidly in the New York metropolitan area before outbreak onset in other urban centres of California, Texas, Illinois, and Florida. We summarize here our MPX clinical experience at our 700-bed, level 1 trauma centre, which serves a large swath of the New York metropolitan area, including the lower Hudson Valley and New York City.

The first case of MPX was seen in our hospital in June 2022, in a patient with recent travel to a large social event for gay and bisexual men in Florida. All patients were seen and treated as outpatients either in our specialized MPX isolation clinic or remotely through telemedicine appointments. Many of the patients referred to us were either treated for Human immunodeficiency virus (HIV) infection or were followed for PrEP. The demographics and clinical presentation of 23 MPX patients are summarized in Table 1. Ten patients had a fever, 10 had genital ulcers, 4 had anal ulcers, and 4 had significant proctitis. Two patients were hospitalized for severe proctitis and fever. Ten patients received 11 fourteen-day courses of tecovirimat under an investigational new drug protocol approved by our institutional review board (IRB) within 72 hours of starting the medication. The indication included presence of anal ulcers and proctitis [8,9]. With the initiation of tecovirimat, anorectal pain and bleeding improved within only 3 days in 4 patients. The resolution of one patient's buttock lesions are shown in Figure 1. The other 6 patients did not notice a marked improvement on therapy but all resolved their symptoms by the end of the 14 days of tecovirimat. No patients noted any side effects attributable to tecovirimat. One HIV positive patient had an especially slow

response to his first course of tecovirimat. His initial symptoms recurred several days after stopping the medication. Physical exam revealed new anal ulcers which were swabbed and found to be MPXV positive and Herpes Simplex Virus 1/2 (HSV) negative. A second course of tecovirimat was given which helped resolve his recurrent symptoms. Five patients had received their first dose of Jynneos vaccine within the week prior to symptom onset.

In an effort to curb the spread of MPXV in our community, we collaborated with our county Department of Health and set up a drive thru vaccination centre using the same structure we used for our COVID19 vaccine drive. Our vaccination efforts targeted at-risk populations as defined by the state health department and vaccinated 1,103 people with over 1,800 doses of Jynneos vaccine [10]. The age distribution of vaccinations reflected the age distribution of clinical cases reported in the literature with the highest numbers of vaccinees aged 25-44 (Table 2, Figure 2). Most of our patients (734 people) were New York State residents and 53 patients came from outside the state for the vaccine. There were 107 African Americans, 82 Hispanic and 418 White individuals with a large number of people opting not to give their race or ethnicity (Table 2).

Monkeypox often manifests as a morbid infection eliciting painful mucositis of the pharynx, urethra, and anus. We observed mixed response to tecovirimat with a minority of patients showing rapid clinical response to tecovirimat while the others showed poor to no response. One challenge we faced was the lack of available testing for at-risk patients who presented with symptoms of MPX without cutaneous manifestations due to current restrictions on sample types acceptable for MPXV testing [11]. Similar to the COVID -19 pandemic, we experienced a rapid, high-impact outbreak of MPX in the New York City metropolitan area, requiring urgent mobilization of healthcare resources and close coordination with local and state departments of health. Public health outreach and engagement of at-risk persons, accurate and timely diagnostics, and availability of an

investigational drug and active mass vaccination allowed for control of this current Monkeypox outbreak [12].

## References:

1. Breman JG, Kalisa R, Steniowski MV, Zanotto E, Gromyko AI, Arita I. Human monkeypox, 1970-79. *Bull World Health Organ.* 1980; 58: 165-82.
2. Lefkowitz EJ, Wang C, Upton C. Poxviruses: past, present and future. *Virus Research.* 2006; 117: 105-18.
3. Arita I, Jezek Z, Khodakevich L, Ruti K. Human monkeypox: a newly emerged orthopoxvirus zoonosis in the tropical rain forests of Africa. *Am J Trop Med Hyg.* 1985; 34: 781-9.
4. Hutin YJ, Williams RJ, Malfait P, Pebody R, Loparev VN, Ropp SL et al. Outbreak of human monkeypox, Democratic Republic of Congo, 1996 to 1997. *Emerg Infect Dis.* 2001; 7: 434-8.
5. Minhaj FS, Ogale YP, Whitehill F, Schultz J, Foote M, Davidson W, et al. Monkeypox Outbreak - Nine States, May 2022. *MMWR Morb Mortal Wkly Rep.* 2022; 71: 764-69.
6. Thornhill JP, Barkati S, Walmsley S, Rockstroh J, Antinori A, Harrison LB et al. Monkeypox virus infection in humans across 16 countries—April–June 2022. *New England Journal of Medicine.* 2022; 387(8):679-91.
7. World Health Organization. 2022 Monkeypox Outbreak: Global Trends. WHO. Oct 31, 2022. [https://worldhealthorg.shinyapps.io/mpx\\_global/](https://worldhealthorg.shinyapps.io/mpx_global/). Accessed Oct 31, 2022.
8. O'Laughlin K, Tobolowsky FA, Elmor R, Overton R, O'Connor SM, Damon IK et al. Clinical Use of Tecovirimat (Tpoxx) for Treatment of Monkeypox Under an

- Investigational New Drug Protocol - United States, May-August 2022. MMWR Morb Mortal Wkly Rep. 2022; 71: 1190-95.
9. Centers for Disease Control [Internet]. Tecovirimat. c2022  
<https://www.cdc.gov/poxvirus/monkeypox/clinicians/Tecovirimat.html> [cited 2022 Oct 23]
  10. Rao AK, Petersen BW, Whitehill F, Razeq JH, Isaacs SN, Merchlinsky MJ et al. Use of JYNNEOS (Smallpox and Monkeypox Vaccine, Live, Nonreplicating) for Preexposure Vaccination of Persons at Risk for Occupational Exposure to Orthopoxviruses: Recommendations of the Advisory Committee on Immunization Practices - United States, 2022. MMWR Morb Mortal Wkly Rep. 2022; 71: 734-42.
  11. Aden TA, Blevins P, York SW, Rager S, Balachandran D, Hutson CL, et al. Rapid Diagnostic Testing for Response to the Monkeypox Outbreak - Laboratory Response Network, United States, May 17-June 30, 2022. MMWR Morb Mortal Wkly Rep. 2022 71: 904-07.
  12. Delaney KP, Sanchez T, Hannah M, Edwards OW, Carpino T, Agnew-Brune C et al. Strategies Adopted by Gay, Bisexual, and Other Men Who Have Sex with Men to Prevent Monkeypox virus Transmission - United States, August 2022. MMWR Morb Mortal Wkly Rep. 2022; 71: 1126-30.

Table 1 – Demographics and clinical outcomes of MPX patients

	Number of patients
Total number of MPX patients	22
Gender	Male (23) Female (0)
Sexual practice	MSM (21) Heterosexual men (2)
Co-morbidities	HIV (10) Diabetes (2) TNF alpha medication (1)
Race/ethnicity	Black/African American (9) Hispanic (10) White (1) Unknown (1)
Co infections	Chlamydia (1) Gonorrhea (1) Syphilis (1)
1 <sup>st</sup> dose Jynneos prior to symptom onset?	No (17) Yes (5)
Presentation	Genital ulcers (10) Anal ulcers (6) Oral ulcer (4) Abscess (2) Urethritis (2) Proctitis (4) Fever (10)

Table 2 - Demographics of Jynneos vaccine recipients

	Number of patients
Home address	New York State outside New York City (734) New York City (117) Out of state (53) Address unavailable (199)
Race/Ethnicity	African American (107) Hispanic (82) White (418) Asian (21) Mixed/other race (70) unknown/refused (405)
age	< 24 years old (105) 25-44 (547) 45-64 (371) >65 (80)

Figure 1





Figure 2

